MBMarina F. Ballyuzek

Marina F. Ballyuzek

*This is an algorithmically generated author record based on publicly available information.

Marina F. Ballyuzek has a total of 46 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Search for cardiotoxicity predictors of immune checkpoint inhibitors: results of a prospective study

    by M. A. Simakova, N. D. Gavriluk, E. A. Kushnareva, T. N. Shuginova, F. V. Moiseenko, E. L. Urumova, E. V. Karelkina, I. A. Pankova, M. F. Ballyzek, O. M. Moiseeva, et al.

    Поиск предикторов кардиотоксических эффектов ингибиторов контрольных точек иммунитета: результаты проспективного исследования

  • Open Access

    Prognostic markers of immune-related adverse events in cancer therapy with checkpoint inhibitors: an uncontrolled, open-label, prospective cohort study

    by V. V. Khizha, D. I. Kozlova, N. A. Klyaus, S. O. Kuzin, G. V. Sholokhov, D. G. Khaimanova, A. G. Vasiliev, M. F. Ballyuzek, Хижа Виталий Валентинович, Кляус Наталья Андреевна, et al.

    BACKGROUND: Immune checkpoint inhibitors are highly effective in treating malignant neoplasms, but they often cause immune-related adverse events. The mechanisms of their pathogenesis are not well understood, and there are no reliable markers in clinical practice for assessing the risk of their occurrence. This study addresses the lack of research by validating a panel of markers. This will allow for personalized preventive management of patients and reduce the frequency of premature treatment discontinuation. AIM: The study aimed to identify the most informative prognostic markers for immune-related adverse events by evaluating dynamic changes in plasma cytokine levels in patients with malignant neoplasms who were receiving checkpoint inhibitor therapy. METHODS: A prospective study of patients with malignant neoplasms receiving checkpoint inhibitor therapy was conducted between 2023 and 2024 at the St. Petersburg Hospital of the Russian Academy of Sciences. The risk of immune-related adverse events was assessed as part of the dynamic observation (105 days with 2.0–2.5-week intervals). The primary endpoint was changes in plasma cytokine concentrations, determined by multiplex analysis and analyzed using nonparametric statistical tests such as the Shapiro–Wilk test, Mann–Whitney U test, and Šidák correction. RESULTS: The study included 21 patients with malignant neoplasms who completed the entire observation program. Six patients (28.6%) developed immune-related adverse events, whereas 15 (71.4%) did not. The development of immune-related adverse events was found to be associated with a significant increase in cytokine concentrations, suggesting a predominance of type 1 and type 17 T-helper cells. Of the evaluated biomarkers, interleukin 12p70 (IL-12p70), IL-15, and transforming growth factor-beta (TGF-β) had the greatest prognostic value for predicting complications. These biomarkers exhibited high sensitivity and specificity in pairwise group comparisons (p 0.005). During the manifestation of immune-related adverse events, the plasma concentrations of the following markers were as follows: IL 12p70: 2.51 [2.09–2.93] pg/mL; TGF-β: 14.54 [13.52–17.12] ng/mL; IL-15: 20.86 [15.51–26.21] pg/mL. The analysis confirmed that these markers are the most reliable predictors of an excessive immune response. No complications unrelated to the primary mechanism of action of the study therapy were reported. CONCLUSION: This study demonstrated for the first time the possibility of a predictive risk assessment for immune-related adverse events prior to checkpoint inhibitor therapy initiation based on IL-12p70, IL-15, and TGF-β levels. These findings allow for personalized patient management strategies that balance treatment efficacy with the prevention of complications. The study had two main limitations: its small sample size (n = 21) and the fact that patients were recruited from a single site.

  • Open Access

    Cardioprotection with levocarnitine intracoronary administration during percutaneous coronary interventions

    by N. Yu. Semigolovskii, M. F. Ballyuzek, S. O. Mazurenko, A. B. Guslev, A. V. Kozaev, E. M. Nikolskaya, I. G. Semenova

    Currently, the number of percutaneous coronary interventions (PCI) performed in acute and chronic forms of coronary heart disease continues to grow: every year their number reaches at least 5,000,000 worldwide, and more than 200,000 of them in Russia. The main causes of postoperative mortality are perioperative myocardial infarction and acute heart failure due to inadequate protection of the myocardium from ischemia/reperfusion under conditions of balloon expansion and stenting of the affected coronary arteries. The review presents experimental and clinical literature data on the successful use of levocarnitine for cardioprotection in patients with various forms of coronary heart disease and patients with chronic heart failure, both with intravenous administration and as part of a cardioplegic solution during heart surgery. The intracoronary route of administration of levocarnitine solution during PCI in high-risk patients (elderly and senile patients, with multivessel lesions of the coronary bed, difficulties in conducting the intervention) is substantiated. The description of two clinical cases of the use of the technique in elderly patients with acute forms of coronary heart disease with multivessel lesion is given. The postoperative period proceeded without complications with smooth dynamics of biomarkers (troponin I, total creatinephosphokinase, MB-fraction of creatinephosphokinase, lactate dehydrogenase), ischemic ECG shifts were little pronounced. The expected results of the application of the technique are a reduction in intraoperative and postoperative complications of ischemia/ reperfusion and an increase in the effectiveness of the clinical results of PCI in high-risk patients.


  • Open Access

    Myocarditis associated with immune checkpoint inhibitor therapies: diagnostic and treatment strategies

    by Марина Баллюзек, Светлана Проценко, Вера Потиевская

    This review aims to provide information on myocarditis and inflammatory cardiomyopathies associated with immune checkpoint inhibitor (ICI) therapies. Additionally, it will present current data on strategies for diagnosis and treatment of these conditions. As immunotherapy becomes more widely used, it has revealed diverse clinical symptoms, courses, and outcomes of cardiovascular immune-related adverse events (irAEs). These range from rare but potentially life-threatening fulminant forms to mild symptomatic courses that can lead to the development of dilated cardiomyopathy, arrhythmias, and heart failure. The review discusses the risk factors and common comorbid clinical conditions of irAE-associated myocarditis, as well as severity assessment and observation algorithms. The importance of a multidisciplinary approach to managing patients with this cardiotoxic irAE is also emphasized. В обзоре представлены сведения о миокардитах и воспалительных кардиопатиях, связанных с терапией ингибиторами иммунных контрольных точек (ИКТ), имеющиеся современные данные о стратегиях их диагностики и лечения. Широкое практическое применение иммунотерапии постепенно стало выявлять разнообразную клиническую симптоматику, течение и исходы иммуноопосредованных кардиологических нежелательных явлений (иНЯ) от достаточно редких, но потенциально жизнеопасных фульминантных форм, до малосимптомных вариантов течения, которые, однако, нередко приводят к развитию дилатационной кардиопатии, аритмий и сердечной недостаточности. Рассматриваются факторы риска, частые сопутствующие клинические состояния иммуноопосредованных миокардитов, вопросы оценки степени тяжести иНЯ, алгоритмы наблюдения. Подчеркивается важность мультидисциплинарного подхода к решению проблем ведения пациентов при развитии этого кардиотоксического иНЯ.


  • Open Access

    Combined immune-mediated adverse events in treatment with immune checkpoint inhibitors

    by Марина Баллюзек, Светлана Проценко, Сергей Кузин, Мария Машкова, Дзераса Хайманова

    We present a clinical case of development of several combined immune-related adverse events (irAEs), i. e. cardiotoxicity (acute myocarditis and pericarditis), pulmonitis, myositis, hematological syndrome and thyroiditis which occurred during the treatment of cutaneous melanoma with an immune checkpoint inhibitor (ICI) ― nivolumab. A case of irAEs combinations, including those considered to be rare, such as myocarditis and hematological syndrome, developing on the background of cancerous symptoms, causes difficulties in diagnostics and can make it difficult to detect the existing pathology in time. This is why such cases require a mandatory involvement of specialized professionals, and there is a need for multidisciplinary cooperationю Moreover, the current case demonstrates the possibility of adding an examination of the musculocutaneous flap to the diagnostic algorithm of ICI-related myocarditis. This will be an additional argument in favor of a diagnosis of myocarditis rather than other cardiotoxic or concomitant heart lesions in case of a confirmed immune inflammation of the muscle ― myositis. The problems of the duration of glucocorticoid therapy and the possibility of continuing immunotherapy in cases of cardiotoxic irAEs of various gradex are discussed Представлен клинический случай развития нескольких сочетанных иммуноопосредованных нежелательных явлений (иНЯ)при лечении меланомы кожи ингибитором иммунных контрольных точек (ИКТ) - препаратом ниволумаб, а именно, кардиотоксических осложнений - острого миокардита и перикардита, пульмонита, миозита, гематологического синдрома и тиреоидита. Случай сочетания иНЯ, в том числе, считающихся редкими, таких как, миокардит и гематологический синдром на фоне симптомов онкологического заболевания, вызывает сложности диагностики, и может затруднить своевременное выявление патологии, поэтому предполагает обязательное привлечение профильных специалистов и необходимость междисциплинарных обсуждений. Случай также демонстрирует возможности дополнить алгоритм диагностики ИКТ-миокардитов исследованием кожно-мышечного лоскута, что при подтверждении иммунного воспаления мышцы - миозита, явится дополнительным аргументом в пользу диагноза миокардита, а не других кардиотоксических или сопутствующих поражений сердца. Обсуждаются проблемы длительности терапии глюкокортикоидами и возможности продолжения иммунотерапии в случаях развития кардиотоксических иНЯ различной степени тяжести.

  • Open Access

    The first and the second types of diabetes mellitus, autoimmune and non-autoimmune thyroiditis differential diagnosis possibility using the calculated index based on plasma butyrylcholinesterase isoforms activity

    by Daria I. Kozlova, Vitaliy V. Khizha, Lyudmila V. Anosova, Anastasia A. Korolkova, Svetlana S. Benevolenskaya, Dmitrii S. Vasilev, Arseny V. Rybakov, Karina A. Yureva, Maria E. Shevaldina, Marina F. Ballyzek

    BACKGROUND: The possibility of using a diagnostic index based on the use of blood plasma objective indicators to differentiate the diagnosis of type 1 and type 2 diabetes mellitus, autoimmune and non-autoimmune thyroiditis is an urgent task for timely decision-making on the use of a particular type of therapy, taking into account the etiology of a particular pathology. Changing the ratio of blood plasma butyrylcholinesterase isoforms activity makes it possible to identify increased excitability, to separate them among themselves depending on the genesis, and during treatment, to assess the activity of diseases and the effectiveness of therapeutic measures. AIM: To develop a calculated diagnostic index for the differential diagnosis of diabetes and thyroiditis autoimmune type from symptomatically similar non-autoimmune pathologies, using the ratio of the plasma pseudocholinesterase isoforms activities. MATERIALS AND METHODS: The study involved 188 people: 45 patients diagnosed with type 1 diabetes; 60 patients diagnosed with type 2 diabetes; 25 patients diagnosed with autoimmune thyroiditis; 25 patients with non-autoimmune thyroiditis; the control group consisted of 33 healthy volunteers. The groups were aligned by gender and age. Patients of all groups were examined by an endocrinologist and a therapeutist. The diagnoses were made in accordance with the Clinical Guidelines of the Russian Endocrinologists Association for the Diagnosis and Treatment of Autoimmune Thyroiditis in Adults, as well as the Clinical Guidelines Type 1 Diabetes Mellitus in Adults. In the blood plasma of all patients groups, the activity of pseudocholinesterase (butyrylcholinesterase) forms was determined by analysis using a modification of the Ellmans method in combination with inhibitory analysis. The index was calculated based on the ratio of the studied enzyme typical and atypical forms activities. Based on the results of data analysis for all examined groups, diagnostic intervals were determined that are characteristic for each diagnosis, as well as for conditionally healthy people. Comparison of the patients distribution by categories of diagnosis was carried out using the -square test with Yates correction in the SPSS 22 statistical software package. RESULTS: The results of the blood plasma analysis determined that in the diagnoses of autoimmune thyroiditis and type 1 diabetes mellitus, there was an increase in the activity of increased activity of the butyrylcholinesterase isoform, while the activity of the atypical form remains more stable. The ratio of these forms was taken as the basis for the development of the calculated diagnostic index. Diagnostic index for the control group in the range of 12; for patients with non-autoimmune thyroiditis 2,12,9; autoimmune thyroiditis 33,5; type 1 diabetes mellitus 3,65; type 2 diabetes 01. Statistical analysis of the data showed that the diagnosis based on the index obtained in this way does not inferior to the diagnostic scales in terms of sensitivity and specificity. The findings are consistent with the evolution of data supporting each diagnosis. CONCLUSIONS: The calculated index on the basis of butyrylcholinesterase activity is a promising, minimally invasive, fast and budgetary method, revealing a pronounced severity of occurrence in terms of symptoms, but different in etiology, type 1 diabetes mellitus and type 2 diabetes mellitus, autoimmune thyroiditis and thyroiditis of a non-autoimmune nature, which is of critical importance when choosing a therapeutic strategy and improving the quality of life of patients.

  • Open Access

    Chronic fatigue syndrome in the routine hematology practice

    by Vsevolod G. V.G.POtapenko, Marina F. Ballyuzek

    Purpose. Presentation of clinical signs and laboratory profiles of the patients with chronic fatigue syndrome, and comparison of their symptoms with those of the patients with iron deficiency anemia. Materials and methods. Retrospective analysis of the patients symptoms referred to the hematologist outpatient clinic during the period between January 2016 and December 2018. Results. There were 560 patients(162 males and 398 females) referred for a primary consultation by a hematologist. Median age was 52.5 (1894) years. The unexplained fatigue was reported by 27 (4.8%) patients (1 male and 26 females), median age 41 (2466) years. Diagnosis chronic fatigue syndrome (CFS) was confirmed based on the criteria in 17 (63%) patients. 10 patients (47%) with symptoms partially meeting the criteria were diagnosed idiopathic fatigue syndrome (SIF). Half of the patients connected the onset of the diseases with emotional trauma (family issues etc.). The prevailing complaints (30%) were represented by: prolonged fatigue, mild memory impairment and distraction, arthralgia and insomnia. The most frequent reason to see a hematologist was fatigue and borderline changes in the blood tests. Five patients with CFS and 2 patients with SIF were known to have previously diagnosed iron deficient anemia (IDA). Median level of hemoglobin in the patients with severe fatigue and IDA was 10.7 (8.411.7) g/dl. Median follow up duration was 28 (640) months. In the observed group (n = 23) 17% of the patients (n = 4) showed spontaneous improvement. The rest of the patients had reported no changes. The comparison group (n = 64) included the patients with IDA. Most of them (n = 38) did not report fatigue as their initial symptoms (median level of hemoglobin was 9.35 (5.511.9) g/dl). Twenty six patients reported fatigue; median level of hemoglobin was 8.15 (5.911.7) g/dl. The difference between the hemoglobin levels in two groups was significant (р 0.05). However, there was no correlation between the level of hemoglobin and fatigue in the patients with CFS and SIF. The correlation was found in the patients with CFS and SIF between fatigue and patients perception. Conclusion. The main symptoms accompanying CFS are fatigue and other non-specific symptoms which are often related to patients emotional status. Considering CFS as a differential diagnosis when dealing with fatigue is essential.

  • Open Access

    Organization of rehabilitation programs for cancer patients based on an interdisciplinary approach

    by M. F. Ballyuzek, A. K. Ionova, M. V. Mashkova, B. P. Stepanov, O. L. Chagunava

    Организация программ реабилитации онкологических пациентов на основе междисциплинарного подхода